We use cookies on this site. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the UW–Madison Cookie Notice.
University of Wisconsin School of Medicine and Public Health
Therapy Research
Image Guidance
This is an accordion element with a series of buttons that open and close related content panels.
The mission of the RED Lab is to advance the beneficial uses of ionizing radiation for cancer treatment. Together with both clinical and industrial partners, the RED Lab identifies future challenges that will likely impede the quality and effectiveness of cancer care to patients. We aim to introduce disruptive ideas and translational technology that will help address these challenges through the use of computational modeling and simulation and instrumentation design and development. While much of our attention is devoted to the advancement of radiation therapy, the laboratory also addresses problems encountered in imaging, immunotherapy, and surgery.
Dr. Block’s research interests include MR angiography and cardiac imaging – specifically designing real-time magnetic resonance acquisition and processing algorithms and systems for these procedures. Dr. Block Profile
Research of the Cai Group is focused on three areas: 1) development of multimodality molecular imaging agents; 2) molecular therapy of cancer; and 3) nanotechnology and its biomedical applications. Although our major disease focus is on cancer, the key feature of molecular imaging/therapy is that it is molecular specific instead of disease specific. The same molecularly-targeted agents can be applied in various diseases as long as the particular target is present or over-expressed. In addition, we are collaborating with a number of research groups both within UW and at other universities, where imaging can serve as an invaluable tool to answer the specific research questions posed.
Dr. Hall’s group is interested in quantifying tissue microstructure using ultrasound imaging. This is accomplished by investigating elastography and acoustic scattering.
Dr. Jeraj’s main research focus is to improve cancer treatment by furthering the understanding of treatment resistance and the impact of tumor heterogeneity on treatment response using molecular imaging. Their work analyzes patient data obtained from clinical trials to implement imaging biomarkers describing heterogeneity to understand both the development of treatment resistance and patient survival. Using the clinical trial data they aim to create models, machine-learning or computational, that further the understanding of disease progression.
The mission of Dr. Speidel’s laboratory is to develop novel imaging tools for interventional radiologists and cardiologists through the application of physics, advanced imaging technology, and innovative algorithms.
This is an accordion element with a series of buttons that open and close related content panels.
The mission of the RED Lab is to advance the beneficial uses of ionizing radiation for cancer treatment. Together with both clinical and industrial partners, the RED Lab identifies future challenges that will likely impede the quality and effectiveness of cancer care to patients. We aim to introduce disruptive ideas and translational technology that will help address these challenges through the use of computational modeling and simulation and instrumentation design and development. While much of our attention is devoted to the advancement of radiation therapy, the laboratory also addresses problems encountered in imaging, immunotherapy, and surgery.
Radiation metrology, including calibration of ionization chambers, calorimetry, free air chambers. Radiation dosimetry in diagnostic radiology brachytherapy, and radiotherapy, quality assurance in radiology and radiotherapy, luminescence for dosimetry (TLD). Wisconsin Medical Radiation Research Center
Dr. Glide-Hurst’s primary areas of research and clinical expertise include magnetic resonance simulation (MR-SIM) and MR-guided radiation therapy.
This is an accordion element with a series of buttons that open and close related content panels.
The mission of the RED Lab is to advance the beneficial uses of ionizing radiation for cancer treatment. Together with both clinical and industrial partners, the RED Lab identifies future challenges that will likely impede the quality and effectiveness of cancer care to patients. We aim to introduce disruptive ideas and translational technology that will help address these challenges through the use of computational modeling and simulation and instrumentation design and development. While much of our attention is devoted to the advancement of radiation therapy, the laboratory also addresses problems encountered in imaging, immunotherapy, and surgery.
Research of the Cai Group is focused on three areas: 1) development of multimodality molecular imaging agents; 2) molecular therapy of cancer; and 3) nanotechnology and its biomedical applications. Although our major disease focus is on cancer, the key feature of molecular imaging/therapy is that it is molecular specific instead of disease specific. The same molecularly-targeted agents can be applied in various diseases as long as the particular target is present or over-expressed. In addition, we are collaborating with a number of research groups both within UW and at other universities, where imaging can serve as an invaluable tool to answer the specific research questions posed.
Dr. Engle’s work is actively pursuing novel accelerator targetry and radiochemistry for the production of radionuclides that are useful in medical diagnosis, disease treatment, basic science and industrial applications.
Dr. Ellison’s research interests utilize the principles and techniques of nuclear and radiochemistry to address challenges in the field of nuclear medicine. Drawing from the fields of nuclear chemical elemental separations, small molecule synthetic radiochemistry, preclinical cancer models, and preparation of radiopharmaceuticals for human research, Ellison’s work focuses on the development of small molecules radiolabeled with matched positron-emitting and Auger-electron-emitting therapeutic radionuclides for the planning and execution of targeted radionuclide therapy of cancer.
